B+
Bull case
25%
Probability
Target price
$27.00
Analysis reference price unavailable
Analysis 2026-10-16 · RankAlpha Sentiment Codex
AKTS
Aktis OncologyDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$16.00
Analysis reference price unavailable
Analysis 2026-10-16 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$8.00
Analysis reference price unavailable
Analysis 2026-10-16 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-10-16
Recent news sentiment (30D)
+0.2
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+61.8
Score
AI commentary
The October 1 BActinium-2 initiation is a confirmed execution positive, but it completes a previously expected milestone rather than adding efficacy evidence. The supplied Q2 snapshot reported a $0.44 loss per share matching its cited consensus and $3.4 million of revenue above its cited $2.3 million forecast. No reliable post-release price reaction, analyst revisions, social coverage, options skew, short-interest or employee-rating data were supplied; zero-valued sentiment fields denote unavailable data, not measured neutrality.
RankAlpha Sentiment Codex - 2026-10-16
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-12-31eventInternal clinical-supply facilityMedium impact
Aktis expected its in-house GMP facility to become operational in H2 2026. Completion could support clinical supply for its radioconjugate trials, but commissioning is an execution milestone, not proof of clinical benefit. [#SEC-8K-2026-08-13]
2027-03-31eventPreliminary AKY-1189 Phase 1b dataHigh impact
Aktis expects preliminary NECTINIUM-2 data in Q1 2027. Early safety and antitumor activity in Nectin-4-expressing cancers could materially change the clinical thesis; enrollment, efficacy and durability remain unproven. [#SEC-8K-2026-08-13]
2027-12-31catalystAKY-2519 therapeutic dataHigh impact
The company expects preliminary BActinium-1 mCRPC data in 2027. Its October 1 release confirmed that the separate BActinium-2 trial in lung and other B7-H3-expressing tumors had begun, fulfilling an earlier initiation milestone; neither trial has established therapeutic efficacy. [#IR-2026-10-01] Aktis release
Recommendation
N/A
No formal recommendation provided.
As of 2026-10-16 • Updated nightlySource: Internal modelMethodology